44-6 Techno 10-ro Yuseong HQ : +82-42-861-4551 info@genomictree.com

Office Address

44-6 Techno 10-ro Yuseong Daejeon South Korea

Phone Number

HQ : +82-42-861-4551

Early Tect : +82-1522-0474

Email Address

info@genomictree.com

R&D

Clinical Studies

Clinical Study of EarlyTect® Colon Cancer

In a pivotal clinical study, EarlyTect® Colon Cancer Test has been proven to be able to diagnose colorectal cancer with 90.2% sensitivity and 90.2% specificity, and 89.1% sensitivity for early stages (0-II) on 585 subjects at Severance Hospital and Health Promotion Center of Severance Hospital. In addition, the sensitivity is not associated with sex, age, tumor stage and tumor location.

EarlyTect® Colon Cancer

(95% CI 85.8-93.6)

Sensitivity of EarlyTect® CRC Test to clinical stages

Clinical Study of EarlyTect® Bladder Cancer

In a pilot clinical study, EarlyTect® Bladder Cancer Test has been shown to be able to diagnose bladder cancer with 84.0% sensitivity and 94.0% specificity,
and 74.0% sensitivity for pTa, early stages of bladder cancer, on 574 hematuria subjects at Chungnam National University Hospital, Konyang University Hospital and Daejeon Catholic St. Mary’s Hospital.

Clinical Study of EarlyTect® Lung Cancer

In a pivotal clinical study, EarlyTect® Lung Cancer Test has been proven to be able to diagnose lung cancer with 77.8% sensitivity and 92.3% specificity,
and 62.2% sensitivity for early stages (I-II) on 522 subjects at Kyungpook National University Chilgok Hospital. In addition, the sensitivity is not associated with tumor stage, smoking history, or age.